Mixed Dyslipidemia research hub

Phase 3 Clinical Study Evaluating Efficacy, Safety, and Tolerability of Obicetrapib Vs Bempedoic Acid to Treat Dyslipidemia in Adults With Primary Non-familial Hypercholesterolemia or Mixed Dyslipidemia at High to Very High Cardiovascular Risk, During a Treatment Period of Approximately 84 Days

This study compares two cholesterol-lowering medicines, obicetrapib and bempedoic acid, in adults with high cholesterol or mixed dyslipidemia. It looks at how well they reduce 'bad' cholesterol (LDL-C) and if they are safe, especially for people at higher risk of heart problems.

Study Evaluating LDL-C Change and Adherence to Inclisiran Lipid-lowering Therapy in ASCVD

This study looks at how well a medicine called inclisiran works for people with high cholesterol and helps prevent heart problems. We want to see if it lowers bad cholesterol and if people stick to taking it as part of their usual care.

Treatment With Bempedoic Acid and/or Its Fixed-dose Combination With Ezetimibe in Primary Hypercholesterolemia or Mixed Dyslipidemia

This study looks at how a medicine called bempedoic acid (alone or with ezetimibe) works in real life for people with high cholesterol. It checks its effects on cholesterol levels, heart health, and any side effects over time.

A Phase 2 Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of ARO-APOC3 in Adults with Dyslipidemia